HRP20190344T1 - Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja - Google Patents

Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja

Info

Publication number
HRP20190344T1
HRP20190344T1 HRP20190344TT HRP20190344T HRP20190344T1 HR P20190344 T1 HRP20190344 T1 HR P20190344T1 HR P20190344T T HRP20190344T T HR P20190344TT HR P20190344 T HRP20190344 T HR P20190344T HR P20190344 T1 HRP20190344 T1 HR P20190344T1
Authority
HR
Croatia
Prior art keywords
leucine
acetyl
pharmaceutically acceptable
acceptable salt
lsd
Prior art date
Application number
HRP20190344TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190344(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of HRP20190344T1 publication Critical patent/HRP20190344T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20190344TT 2016-08-11 2017-08-11 Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja HRP20190344T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders
EP17767933.9A EP3359146B1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Publications (1)

Publication Number Publication Date
HRP20190344T1 true HRP20190344T1 (hr) 2019-04-19

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20190344TT HRP20190344T1 (hr) 2016-08-11 2017-08-11 Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja
HRP20210153TT HRP20210153T1 (hr) 2016-08-11 2021-01-29 Farmaceutski sastavi i uporabe usmjerene prema poremećajima lizosomskog skladištenja

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210153TT HRP20210153T1 (hr) 2016-08-11 2021-01-29 Farmaceutski sastavi i uporabe usmjerene prema poremećajima lizosomskog skladištenja

Country Status (30)

Country Link
US (4) US11400067B2 (https=)
EP (4) EP3482754B1 (https=)
JP (4) JP7393943B2 (https=)
KR (4) KR20220154849A (https=)
CN (3) CN109843275B (https=)
AU (3) AU2017308864B2 (https=)
CA (1) CA3033557A1 (https=)
CY (2) CY1121345T1 (https=)
DK (2) DK3359146T3 (https=)
ES (2) ES2849566T3 (https=)
FI (1) FIC20260014I1 (https=)
HK (1) HK1253282B (https=)
HR (2) HRP20190344T1 (https=)
HU (2) HUE052837T2 (https=)
IL (2) IL314107A (https=)
LT (2) LT3482754T (https=)
MA (2) MA43876B1 (https=)
MD (2) MD3359146T2 (https=)
ME (1) ME03340B (https=)
MX (2) MX384447B (https=)
NZ (3) NZ790895A (https=)
PL (2) PL3482754T3 (https=)
PT (2) PT3482754T (https=)
RS (2) RS61442B1 (https=)
RU (1) RU2749515C2 (https=)
SG (1) SG11201901048VA (https=)
SI (2) SI3359146T1 (https=)
SM (2) SMT202100050T1 (https=)
TN (1) TN2019000032A1 (https=)
WO (1) WO2018029657A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) * 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
AU2001269923A1 (en) 2000-06-19 2002-01-02 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Also Published As

Publication number Publication date
AU2023202903A1 (en) 2023-05-25
CY1121345T1 (el) 2020-05-29
SMT201900154T1 (it) 2019-05-10
ES2716133T3 (es) 2019-06-10
RU2021115932A (ru) 2021-06-08
US12433862B2 (en) 2025-10-07
LT3482754T (lt) 2021-05-10
NZ790894A (en) 2026-03-27
JP2025188157A (ja) 2025-12-25
CY1123844T1 (el) 2022-05-27
JP7393943B2 (ja) 2023-12-07
MD3482754T2 (ro) 2021-05-31
RS58478B1 (sr) 2019-04-30
IL314107A (en) 2024-09-01
EP3482754A1 (en) 2019-05-15
CN109843275A (zh) 2019-06-04
US12433863B2 (en) 2025-10-07
RU2019106493A3 (https=) 2020-10-26
US20190201359A1 (en) 2019-07-04
CN121360108A (zh) 2026-01-20
FIC20260014I1 (fi) 2026-04-27
MX384447B (es) 2025-03-14
SI3359146T1 (sl) 2019-05-31
US20240197663A1 (en) 2024-06-20
NZ790895A (en) 2026-03-27
EP3482754B1 (en) 2020-12-23
US11400067B2 (en) 2022-08-02
PL3359146T3 (pl) 2019-07-31
IL264610B1 (en) 2024-08-01
MX2019001577A (es) 2019-08-29
SMT202100050T1 (it) 2021-03-15
HUE041914T2 (hu) 2019-06-28
KR20220044372A (ko) 2022-04-07
EP3359146A1 (en) 2018-08-15
ES2849566T3 (es) 2021-08-19
IL264610A (en) 2019-02-28
EP3865126A1 (en) 2021-08-18
KR20190039226A (ko) 2019-04-10
US20260027077A1 (en) 2026-01-29
HK1253282A1 (en) 2019-06-14
AU2017308864B2 (en) 2023-06-01
CA3033557A1 (en) 2018-02-15
KR20240110078A (ko) 2024-07-12
HRP20210153T1 (hr) 2021-05-28
MA43876A (fr) 2018-08-15
ME03340B (me) 2019-10-20
KR102412724B1 (ko) 2022-06-23
AU2025203479A1 (en) 2025-05-29
AU2017308864A1 (en) 2019-02-21
PL3482754T3 (pl) 2021-07-05
IL264610B2 (en) 2024-12-01
BR112019002719A2 (pt) 2019-05-14
SG11201901048VA (en) 2019-03-28
JP7757446B2 (ja) 2025-10-21
MX2021008432A (es) 2021-08-19
MD3359146T2 (ro) 2019-04-30
JP2019524821A (ja) 2019-09-05
PT3359146T (pt) 2019-03-27
MA55947A (fr) 2022-03-23
PT3482754T (pt) 2021-02-03
KR20220154849A (ko) 2022-11-22
RU2749515C2 (ru) 2021-06-11
WO2018029657A1 (en) 2018-02-15
LT3359146T (lt) 2019-04-25
TN2019000032A1 (en) 2020-07-15
AU2023202903B2 (en) 2025-03-06
JP2022050564A (ja) 2022-03-30
DK3359146T3 (en) 2019-04-08
RS61442B1 (sr) 2021-03-31
EP4342461A2 (en) 2024-03-27
HK1253282B (en) 2020-02-07
SI3482754T1 (sl) 2021-04-30
DK3482754T3 (da) 2021-02-01
CN121360107A (zh) 2026-01-20
KR102467953B1 (ko) 2022-11-16
CN109843275B (zh) 2026-04-24
NZ750391A (en) 2026-03-27
EP4342461A3 (en) 2024-05-29
RU2019106493A (ru) 2020-09-11
MA43876B1 (fr) 2019-04-30
HUE052837T2 (hu) 2021-05-28
JP2024059863A (ja) 2024-05-01
US20220331278A1 (en) 2022-10-20
EP3359146B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
HRP20190344T1 (hr) Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja
Bionorica Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis
IL270930A (en) Oligosaccharide-protein conjugates
MX395710B (es) Composiciones gomosas de multicomponentes con nucleo duro.
JP2019524821A5 (https=)
Kamble et al. Anti-inflammatory activity of Raphanus sativus L in acute and chronic experimental models in albino rats
Rezaeipour et al. Efficacy of a persian medicine herbal compound (Alcea digitata alef and malva sylvestris l.) on prevention of radiation induced acute mucositis in patients with head and neck cancer: A pilot study
HRP20251256T1 (hr) Kombinirana terapija sa acetil-leucinom i miglustatom za liječenje lizosomske bolesti nakupljanja
Morazzoni et al. SAMITAL®: a new botanical drug for the treatment of mucositis induced by oncological therapies
Summers et al. Complex antioxidant blend improves memory in community-dwelling seniors
Bertoglio et al. Management of gastrointestinal mucositis due to cancer therapies in pediatric patients: results of a case series with SAMITAL®
WO2017178897A3 (en) Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
WO2006054921A3 (en) Anti-inflammatory extract and agent and method for the production thereof
EP4674435A3 (en) Composition having improved voluntary acceptance
DE202008007923U1 (de) Suppositorium
WO2016175589A3 (ko) 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물
EP4042999C0 (en) SOLID ORAL MEDICATION RECEIVING DEVICE, AND ORAL ADMINISTRATION DEVICE INCLUDING IT
Garrido-Suárez et al. Mangifera indica L. extract tablets supplementation in patients with knee osteoarthritis pain. A controlled pilot study
HRP20171177T1 (hr) Formulacija koja obuhvaća spoj benzotiazolona
Arunkumar et al. A single centre, prospective, randomized, open labelled clinical study to evaluate the effectiveness of Siddha Poly Herbal Formulation, Viprotm, towards the management of uncomplicated respiratory infection
DE102010021842A1 (de) Thymian/Primel oder Efeu zur Behandlung von chronischobstruktiven Lungenerkrankungen (COPD)
CN106540057A (zh) 一种治疗风寒风热的感冒药
EP4647130A3 (en) Pharmaceutical composition comprising eliglustat
Keyßer et al. Recommendations of the DGRh Committee on Complementary Medicine and Nutrition on the application of selected phytotherapeutic drugs and herbal medicines in rheumatology
EP3103438B1 (en) Topical nasal compositions containing xyloglucans for use as decongestans